VICTORIA TIMMERMANS: Open Payments
NPI 1821613811 · CLEVELAND, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$975 in 48 payments from 16 companies in 2025. Trend: 2023 $197 · 2024 $775 · 2025 $975
Food & beverage: $975
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 4 | $166 |
| PFIZER INC. | 8 | $148 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $99 |
| Actelion Pharmaceuticals US, Inc. | 1 | $95 |
| AstraZeneca Pharmaceuticals LP | 5 | $92 |
| Novo Nordisk Inc | 4 | $80 |
| Amgen Inc. | 4 | $74 |
| GlaxoSmithKline, LLC. | 2 | $35 |
| ABBVIE INC. | 2 | $32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $31 |
Products named: ZEPBOUND, CAPLYTA, UPTRAVI, ELIQUIS, OTEZLA, MOUNJARO, FARXIGA, BREZTRI.
Industry payments across GA — which companies pay providers there.
